Conclusion
Plasma cell leukemia is indeed a rare and aggressive subtype of multiple
myeloma with a poor prognosis. The diagnosis can be challenging,
especially in resource-limited settings where access to advanced
diagnostic tools may be limited. Additionally, the lack of clear
evidence for an ideal therapeutic regimen adds to the complexity of
managing this condition. Despite these challenges, a meticulous clinical
approach is crucial to reaching a correct diagnosis and providing
appropriate care for patients with plasma cell leukemia.